Patent ID: 6740325
Filing Date: 2004-05-25
Classification: A61K,A61P,C12N

Abstract:
A human synthetic peptide-based influenza vaccine, comprising: at least four epitopes of influenza virus, said influenza virus epitopes being reactive with human cells, said epitopes comprising:(a) at least one B-cell hemagglutinin (HA) epitope comprising the influenza virus hemagglutinin epitope 91-108 according to SEQ ID NO:1; (b) at least one T-helper hemagglutanin (HA) epitope comprising the influenza virus hemagglutinin epitope 307-319 according to SEQ ID NO: 2 that can bind to many HLA molecules; and (c) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) epitopes comprising the influenza virus nucleoprotein (NP) NP335-350 epitope according to SEQ ID NO:4 and the NP380-393 epitope according to SEQ ID NO:5 that are the most prevalent HLA molecules in a Caucasian human population, such that maximum stimulation of an immune system of a human subject occurs through a combination of at least two epitopes not being selective for a human population, and at least two epitopes being selective for a human population.